A large, international randomized placebo-controlled trial of FGF21 plus semaglutide versus either alone is underway to examine the clinical utility of a combination in patients with MASH stage 2–4 fibrosis in improving fibrosis stage by ≥1 stage. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.